Elucirem
Phase 3Small molecule
Elucirem is one of 3 small molecule programs targeting Contrast Agent. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2 competitors in Contrast Agent
#DrugCompanyPhaseTrials
1Elucirem
GGuerbet
Approved
Elucirem
JJohns Hopkins University
Phase 3
Golytely
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Elucirem. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- JJohns Hopkins University